Special Drug Use Results Survey for the use of Symtuza in pregnant women

Special Drug Use Results Survey for the use of Symtuza in pregnant women - Special Drug Use Results Survey for the use of Symtuza in pregnant women

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037488

Enrollment

Registered

2019-07-26

Start date

2019-07-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV/AIDS

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with HIV infection, who receive Symtuza during pregnancy and whose outcome of pregnancy can be confirmed.

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
Safety (ADR) Effectiveness(Changes in HIV-RNA level, Changes in CD4 lymphocyte count)	—

Countries

Japan

Contacts

Public ContactKazuyo Izumiya

Janssen Pharmaceutical K.K. Post-approval Delivary Unit

kizumiya@its.jnj.com03-4411-5464

Outcome results